There has been exciting news for celiac disease at this year’s Digestive Disease Week (DDW), the massive medical meeting for gastroenterologists worldwide, currently being held in San Diego, CA. Garnering the lead talk in a plenary session, Anokion SA, a clinical stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, released successful results from their Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial and announced that they will be moving forward with Phase 2 trials later this year.
KAN-101 is an investigational drug that seeks to train the body through liver function to ignore the immune response to gliadin – a key component of gluten – in celiac patients, while leaving the healthy elements of the immune system intact. It is a novel approach for a liver-targeted treatment that may have applications for other diseases. Celiac disease is the first proposed application of the strategy.
The Celiac Disease Foundation is proud to have partnered with Anokion and the celiac community to recruit patients through our iQualifyCeliac Study Screening platform for the ACeD Phase 1 trial. We look forward to continuing this work for the Phase 2 trial.
We will be sharing more details about Anokion’s Phase 1 trial results in the coming weeks, as well as how you can participate in clinical trials that are leading to treatments and a cure for celiac disease.
Would you like to participate in celiac disease research? Join the thousands of others in the iCureCeliac® patient registry who are providing critical insights into life with celiac disease. Your participation will help create better diagnostic tools and treatments, governmental policy changes, and access to new and innovative clinical trials nationwide, which may, one day, cure celiac disease.
Join iCureCeliac® here.